Jennifer Marvin-Peek

14PUBLICATIONS
87CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 06, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

|Mar 30, 2026
Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatment.

Jennifer Marvin-Peek, Wei-Ying Jen, Farhad Ravandi

|Feb 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

Jayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero

|Nov 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek

|Nov 20, 2025
Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?

Jennifer Marvin-Peek, Courtney D DiNardo

Pageof 3

Frequent Collaborators

10 joint publications

Courtney D DiNardo

7 joint publications

Naval G Daver

6 joint publications

Nicholas J Short

5 joint publications

Hagop M Kantarjian